Regenerx Biopharm OTC Stock Insiders

RGRX Stock  USD 0.0003  0.00  0.00%   
Regenerx Biopharm employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 68 years, averaging almost 22.0 years of service per executive, having 1.0 employees per reported executive. Break down of Regenerx Biopharm's management performance can provide insight into the company performance.
J Finkelstein  CEO
CEO and President and Director
Allan Goldstein  Chairman
Founder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory Board
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenerx Biopharm In. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in real.

Regenerx Biopharm Management Team Effectiveness

The company has return on total asset (ROA) of (0.8397) % which means that it has lost $0.8397 on every $100 spent on assets. This is way below average. Regenerx Biopharm's management efficiency ratios could be used to measure how well Regenerx Biopharm manages its routine affairs as well as how well it operates its assets and liabilities.
Regenerx Biopharm has a total of 143.55 Million outstanding shares. Regenerx Biopharm has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Some institutional investors establish a significant position in otc stocks such as Regenerx Biopharm in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Regenerx Biopharm, and when they decide to sell, the otc stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Regenerx Biopharm Workforce Comparison

Regenerx Biopharm In is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 75.0. Regenerx Biopharm holds roughly 3.0 in number of employees claiming about 4% of equities under Health Care industry.

Regenerx Biopharm Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Regenerx Biopharm Price Series Summation is a cross summation of Regenerx Biopharm price series and its benchmark/peer.

Regenerx Biopharm Notable Stakeholders

A Regenerx Biopharm stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Regenerx Biopharm often face trade-offs trying to please all of them. Regenerx Biopharm's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Regenerx Biopharm's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
J FinkelsteinCEO and President and DirectorProfile
Allan GoldsteinFounder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory BoardProfile
Nabila TurjmanEx AffairsProfile
String symbol = request.getParameter("s");

About Regenerx Biopharm Management Performance

The success or failure of an entity such as Regenerx Biopharm often depends on how effective the management is. Regenerx Biopharm management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Regenerx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Regenerx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland. REGENERX BIOPHARMACEUTICA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
The data published in Regenerx Biopharm's official financial statements typically reflect Regenerx Biopharm's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Regenerx Biopharm's quantitative information. For example, before you start analyzing numbers published by Regenerx accountants, it's essential to understand Regenerx Biopharm's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Regenerx Biopharm's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Regenerx Biopharm In. Check Regenerx Biopharm's Beneish M Score to see the likelihood of Regenerx Biopharm's management manipulating its earnings.

Regenerx Biopharm Workforce Analysis

Traditionally, organizations such as Regenerx Biopharm use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Regenerx Biopharm within its industry.

Regenerx Biopharm Manpower Efficiency

Return on Regenerx Biopharm Manpower

Revenue Per Employee25.6K
Revenue Per Executive25.6K
Net Loss Per Employee532.6K
Net Loss Per Executive532.6K
Working Capital Per Employee268.7K
Working Capital Per Executive268.7K

Additional Tools for Regenerx OTC Stock Analysis

When running Regenerx Biopharm's price analysis, check to measure Regenerx Biopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenerx Biopharm is operating at the current time. Most of Regenerx Biopharm's value examination focuses on studying past and present price action to predict the probability of Regenerx Biopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenerx Biopharm's price. Additionally, you may evaluate how the addition of Regenerx Biopharm to your portfolios can decrease your overall portfolio volatility.